Science topic
Neurological Diseases - Science topic
Explore the latest questions and answers in Neurological Diseases, and find Neurological Diseases experts.
Questions related to Neurological Diseases
In the identified case of familial desminopathy (T341P DES mutation in heterozygous state), the son has bradycardia, but the father did not have bradycardia. How can this fact be explained?
It is known that patients with desminopathy often die from pneumonia. Have pathomorphological studies of the lungs been performed in patients with desminopathy?
Hello all, my name is Gift Adene, I live in Nigeria, and I'm currently working on an exciting research aimed at developing a CNN model for detecting and predicting neurological diseases!
I'm on the lookout for high-quality and recent data sets that would be suitable for training and testing the CNN model. If you have access to any data sets related to neurological diseases (PD and/or AD preferably), I would love to hear from you!
Also, I'm seeking insights on which data set would be better suited for training the CNN model. Do you have any recommendations or suggestions on the most effective data sets for this purpose? Your expertise and input would be incredibly valuable.
Thanks in advance for your support and assistance, looking forward to a positive response.
#Research #Neurology #MachineLearning #DataScience #HelpNeeded #CNN #ConvolutionalNeuralNetworks
It is known that in the early stages of desminopathy the muscles most often affected are: Semitendinosus, Gracilis and Sartorius. What is the reason for the damage to these particular muscles?
In a patient with desminopathy (mutation Thr341Pro DES in the heterozygous state) with the progression of the disease, we note signs and symptoms that are also characteristic of botulism: bradycardia, arrhythmia, AV blockade, a significant decrease in the average duration of motor unit potentials according to electroneuromyography, paresis and paralysis of the striated muscles, decreased sweating, paresis of the gastrointestinal tract, dry eyes, dry mouth, symmetry of neurological symptoms, hoarseness, impaired visual acuity, doubling of objects occurs, progressive muscle weakness. These signs and symptoms are characteristic of botulism, only when a case of desminopathy is detected, they proceed slowly.
When staining with hematoxylin and eosin of a muscle biopsy from a patient with T341P desminopathy, we observe accumulations of inclusions similar to nuclei (arrows in figures 1 and 2, x280). And outside of these accumulations - adipose tissue, which used to be muscle tissue. There are no such massive accumulations of inclusions in adjacent muscle fibers. We assume that clusters of inclusions are not nuclei? Figure 2 is the inverted figure 1.


I want to study the neuroprotection of ghrelin in mice neurological disease model, but there is differences in this drug between human and rat, which one i should choose since both type of drug has been used in the published paper. Thanks.
A patient with desminopathy survived Covid-19 six months ago without pneumonia, but with a temporary loss of smell and taste. After Covid-19, we note an accelerated progression of desminopathy, penetration accelerates, new muscles are quickly involved in the pathological process, muscle mass decreases, and heart function worsens. Perhaps the infection or its consequences are somehow connected with the mechanism of progression of desminopathy?
To save life in desminopathy, can the body purposefully reduce muscle mass, for example, due to decreased heart function or for another reason?
It is known that when hypothermia, the body sacrifices limbs for survival. Is it possible with desminopathy a similar phenomenon?
Many published articles shows that some drugs have the neuroprotective effect on the neurological diseases. But when it comes to how it could reach the place where it exert its effect, it is unclear. So does it really have the neuroprotective effect or just meaningless results.
I want to find the target receptor for a ligand ,whose effects can be beleived to vary in physiological system of underdeveloped or new born pupps than in adult dogs. How to find the function and mechanism of the same ligand in mice models ,for the treatment of neurological disorders in dogs.
Dear Colleagues, there is a 67 year old female patient with focal edema of frontal, parietal and temporal right side cerebral lobes, with slight dislocation of median brain structures on MRI, no enhancing contrast regions. Sick for 1,5 months, symptoms: fatigue, slight ataxia, slow thinking, no headache. Exam: slowliness of all types actions. No signs of compromised immunological status, no signs of infections. MRI performed twice: 25 september and 20 october, looks almost the same. Some ideas? thank you!


In a patient with hereditary desminopathy (mutation Thr341Pro DES in the heterozygous state) over the past three years, an increase in the blood uric acid level up to 440-480 µmol / l was established by 1.5 times (the norm is 428.4 µmol / l). With the progression of the disease, the level has risen and is above normal. It is known that uric acid is an antioxidant. Is it necessary to reduce the level of uric acid?
The patient has no problems with the joints.
How Does COVID-19 Affect the Brain? Are there implications of COVID-19 in Neurological Disorders?
In the aftermath of the 1918 Spanish Flu pandemic there was a marked increase in incidence in psychological and psychiatric illness incidence. These conditions now often referred to generically as post-viral syndrome increased hospital admissions and treatment of mental health disorders in the years following the outbreak in 1918.
Population studies in countries that did not take part in World War One seem to indicate that the possible post war melancholy could be ruled out as a confounder as this increased incidence was seen in all countries affected by the flu that had been non-combattants in WW1.
Could there be a lasting and chronic element to all SARS type respiratory disorders?
SARS genome sequences have been detected in the brain of earlier SARS autopsies with LM, EM, and with real-time RT-PCR. The signals were confined to the cytoplasm of numerous neurons in the hypothalamus and cortex. Oedema and scattered red degeneration of the neurons was identified in the brains of 80% of the confirmed cases of SARS examined.
SARS viral sequences and pathologic changes have not been found in the brains of unconfirmed cases or control cases.
We may have a longer lasting health care problem that will affect those 'recovered' from Covid-19 for some years to come.
Over the past three years, a patient with hereditary desminopathy (Thr341Pro DES mutation in the heterozygous state) has an uneven decrease in muscle strength in the hands. In the right hand, the decrease in muscular strength in the last three years is 2.1 times, and in the left one - 1.5 times. In a weaker limb, the disease progresses faster. A similar pattern is observed in the legs. The father of the patient had the same changes.
A patient with hereditary desminopathy (mutation Thr341Pro DES in a heterozygous state) with disease progression has a significant decrease in taste. How can this fact be explained?
In a patient with hereditary desminopathy (Thr341Pro DES mutation in a heterozygous state) with disease progression, a significant decrease in olfaction is noted. How can this fact be explained?
Within three years, a patient with a desminopathy (Thr341Pro DES mutation) was found to have a 17% increase in the level of C4 complement components to 0.41 g / l (Norm 0.1-0.4 g / l).
Immune system and Inflammation impact on the Gut-Brain axis !
The Gut/Immune/Nervous (GIN) communication
New insights into how immune system and inflammation play a role in Parkinson's Disease
Nov. 2019
New research indicates that the earliest stages of Parkinson's disease (PD) may occur in the gut with a likely relation to inflammatory bowel disease (IBD).
Parkinsonism is not just a brain disorder, but a group of diseases that may have their onset in the GIT. It is strongly suggested that individuals with an increased tendency for peripheral inflammation have a higher risk to acquire PD. Given the potentially critical role of gut pathology in the pathogenesis of PD, IBD may impact PD risk.
Peripheral immune system alterations may play a role in PD, which has the potential for new therapeutic strategies. Understanding and appreciating the importance of the so-called gut-brain axis, the connection between gut and the brain in PD, has grown rapidly in recent years.
The inflammatory processes have naturally led to discussion of an association between IBD and PD since the two share some basic characteristics. IBD is currently considered an inappropriate immune response to the microbiota in the intestines, characterized by chronic pro-inflammatory immune activity, a trait now also suggested to be a fundamental element of neurodegenerative disorders.
Highlighting the relevance of the immune system, large genome-wide association studies (GWAS) and pathway analyses identified 17 shared loci between PD and seven autoimmune diseases including celiac disease, rheumatoid arthritis (RA), type 1 diabetes, multiple sclerosis, psoriasis, ulcerative colitis and Crohn's disease.
Many epidemiological and genetic studies have found that there seems to be an increased risk of developing PD among people with IBD. The association between IBD and PD may simply be that IBD is just one type of intestinal inflammation, so it is not IBD specifically that increases the PD risk but perhaps intestinal or peripheral inflammation in a broader sense.
Inflammation of the gut is only one of many symptoms on the list of changes in the gut and is associated with neural structures in PD patients. Thus, IBD might be just one of many sources of intestinal inflammation.
While IBD patients are more likely to get PD, the risk is still very small. Yet, for a given IBD patient, the probability of not getting the diagnosis is 95%-97%.
Future pharmacological therapies aiming at slowing or stopping PD progression should not only target patients well into the course of the disease, but also be administered to patients in the very early phases of the disease or at risk for developing PD.
Clinicians should be aware of early Parkinsonian symptoms in IBD patients but also in patients with chronic inflammatory disorders.
A focus on the potential role of the immune system and of systemic inflammation these neurological diseases is encouraged.
A clear knowledge of the mechanisms implicated in Gut/Immune/Nervous communication could help improve the prognostic and therapeutic tools leading to better quality of life for patients, reducing the exacerbation of PD symptoms, and delaying the progression of the disease.
Parkinson's disease is a slowly progressive disorder that affects movement, muscle control and balance. It is the second most common age-related neurodegenerative disorder affecting about 3% of the population by the age of 65 and up to 5% of individuals over 85 years of age. During the 20th century, PD was thought to be primarily a brain disorder, however, research has shown that it may actually begin in the enteric nervous system, the part of the autonomic nervous system that controls the gastrointestinal organs.
Source: Brudek, T. et al. (2019) Inflammatory Bowel Diseases and Parkinson’s Disease. Journal of Parkinson's Disease. doi.org/10.3233/JPD-191729
A patient with hereditary desminopathy (Thr341Pro DES mutation in a heterozygous state) was recommended to refuse toothpaste. He continued to brush his teeth twice a day with a toothbrush with only water. As a result, within one month we noted a significant increase in strength and muscle mass in this patient. The patient did not take any medications during this period. After 30 days, the muscle condition returned to its original level. How can this positive effect be explained?
In a patient with hereditary desminopathy (Thr341Pro DES mutation in the heterozygous state), a significant loss of muscle mass is observed after a night's sleep, with its replacement by adipose tissue. How to reduce muscle loss during sleep?
Food as a culprit in devolvement of neurologic diseases is not a novel concept, as there is a history of specific neurologic diseases that are caused by deficiencies in nutrition, namely lack of certain foods in human diet, like vitamins. There are also diseases caused by excess of some nutrients, and even vitamins. This review, however, is not about these well-known conditions. It is about potential indirect effect of what is considered a “healthy” balanced diet in development of neurologic diseases. We discuss what is known about gluten sensitivity and neurologic disorders, and we extrapolate that there might be a much wider array of intolerances-sensibilities which don’t have yet an objective marker. We also expanded on a hypothesis that maybe other neurologic disorder with immune mechanism like MS might be a target of immunological overload of other antigens apart from gluten.
Joint pain is a very common problem with many possible causes - but it's usually a result of injury or arthritis.
Due to the fact that anxiety can increase long term stress, the risk of of inflammation is high. I think This inflammation can cause pain and swelling in joints, affecting every day movements.
Mobility may be limited due to accident,any complications, neurological diseases and muscle diseases
Neurological disorders in Pakistan
I wish to look at gliosis in a dish, basically the neurons start becoming apoptotic and glial cells come to the rescue. But if I have a patient neurons, how do I mimic this event? Any idea what can be used a control?
Hi,
I'm looking papers about diet intervention in patients suffering from Alzheimer disease. Have you seen any?
Thanks,
Mikołaj
A patient with hereditary desminopathy (a mutation of Thr341Pro DES in a heterozygous state) with the progression of the disease has been established for a long-term healing of skin tissue when it is damaged, compared with a healthy person. The blood sugar level of a patient with desminopathy is normal.
Stem cells treatment is effective in neuroscience and cells available from dental pulp may be used to treat neurological disease
I recently worked on a client/patient who had suffered for a week from a migraine. Massage therapy to the cervical soft tissues and suboccipital areas as well as to the masseter and facial areas did not resolve the pain.
Over the past four years, in a patient with desminopathy (Thr341Pro DES mutation in the heterozygous state), the majority of antioxidant status indicators increased 1.2-2.0 times. Including glutathione in the blood increased 1.8 times to a value of 896 μmol / l (the norm of 500 - 1500 μmol / l), and the level of coenzyme Q10 in the blood increased 1.8 times to a value of 0.8 mg / l (norm 0,4 - 1,6 mg / l), vitamins E and C increased by 1.3 times, respectively, to 6.4 and 6.2 μg / ml.
In the literature there are conflicting data on their effect on the human body.
Over the past six months, a patient with hereditary desminopathy (Thr341Pro DES mutation in the heterozygous state) has a 1.6-fold increase in the level of the pro-inflammatory cytokine interleukin-6 to a value of 8.77 pg / ml (<7.00 pg / ml).
In addition, several parameters indicate the presence of inflammation: an increase in the number of immunity cells with markers CD25 +, CD95 +, HLA-DR + in the T-cell link; as well as an elevated level of C4 complement components.
The level of other cytokines Il-1β, Il-8, Il-10, TNF-α is normal.
At the same time, the immunoregulatory index fell below the norm and is 1.19.
Details are indicated in the questions of this project "myofibrillar myopathy".
Dear scientists, please, join the discussion on this issue, do not limit yourself to viewing only. Ask me additional questions, send messages to your personal mail. Ready to answer any questions and listen to wishes.
Some rare references nowadays focus on autoimmune neurologic diseases triggered by some vaccines such as flu vaccine . I want to estimate incidence rate of this subject annually... Can anyone help me?
Question: Why are the results from science about treatment so difficult to implemented in therapy, especially by neurological diseases? Is that because there is still no integration between therapy and science ? And exist this barrier also because science don’t follow the patient in daily life and on the therapy ward! Or in other words to many investigation in the lab. and not in daily life situation. And is there an listening to each other? My experience is that many scientist do the story and leave and have not the time to listen to the stories of the floor !
I am planning to conduct a neurotoxicity assay using differentated neuro-2a cells. The protocol I am following recommends the use of poly-D lysine for cell attachment. However, we already have poly-L lysine in the laboratory. Will the use of poly-L lysine, instead of poly-D lysine, cause a huge difference in the differentiation, viability, and/or attachment of neuro-2a cells? Thank you very much.
I'm looking to implant a cannula into lateral ventricles of 21-day old mice (13-16g). Does anyone have stereotaxic coordinates for mice this age/size?
C9orf72 is an expansion related to some neurological diseases such as ALS or dementia.
Hi. As we know by stimulating special cells, doctors and scientists are able to transfer different senses such as pain to patients. Now the question is: "Is it possible to import specific data such as words in other languages to brain by extracellular stimulation? "
Currently, our team is working on mechanistic studies of two compounds which are acting in presence of a Biocatalyst having a particular residue highly important for carrying out reaction at room temperature.
After taking that residue (which is important for interaction) along with reactants, we are trying to find out the transistion state using QST2 method. we have already performed the optimization of reactants and the final product formed was obtained with Nimag value = 0.
While performing QST2 OPT+FREQ calculation it always gave an error how - Add virtual bond connecting atoms between atom a(assumption) and b(assumption).
termination is by LNKE error...
Hello,
For my research, people with Parkinson's disease need to perform a computer based cognitive task. I am looking for
a) simple vision screening questionnaire
b) suggestions for exclusion criteria for IRB purposes.
If there is any research about diabetic neuropathy, please share the information here. I really need it for my research. Thanks in advance.
I want to understand how quantum entanglement effects the neurons and the possible relationship between this and certain neurological disorders.
There were complications e.g. hemiplegi
In my experience, I observe that some patients cannot cough willingly, whereas the request is understood and the cough reflex is effective. Could I call this "cough apraxia" ?
Is it the same altered brain pattern that in bucco-facial apraxia ?
I have visited an 29-year old man from Mali with signs of lower motoneurons (bulbar, upper limbs), resembling ALS. He travelled for 8 months from Mali to Italy in extremely hard conditions. Does someone know whether there are some toxic or infectious agents that can mimic ALS?
Thank You
Nowadays, most of oral drugs available for the treatment of epileptic seizures are anticonvulsants. However, most of temporal lobe epilepsy (TLE) seizures do not manifest in convulsions. I heard something about a new therapy with antiepilergic drugs that aims to modulate the neurotransmitter function (i.e., GABA) but I do not know the effectivity of this last.
I would like to ask the expert community about the new approximations to this complex disorder (benefits/side-effects) and more specifically if you recommend to try another pharmacological treatment different from antiepilergic drugs in the case of TLE.
Thanks in advance,
Good day all , I am planning to do an intensive program for diplegic cerebral palsy children , and I am looking for a good assessment tool to measure their improvement before and after the therapy , can anyone give me an advice of which assessment is the best in this case ?
In many cases, neurological score and infarct volumes of MCAo/reperfusion (M/R) induced brain damage correlates. I mean if infarct volume is improved so does the neurological functions. However, sometime I experienced that there is no change in the infarct volumes but the neurological deficit is improved after drug treatment in M/R mice. For the confirmation I repeated the experiment but get the same results. I am using modified neurological severity score (mNSS) that is 18 point scaling for neurological deficit evaluation. To strengthen my findings, I need some published proof. Could you please help me? I have got 1 paper (but low impact journal) and need few more.
Hello, dear neuroscientists.
I have several patients with severe epileptic syndrome, who suffer from often condition of Status Epilepticus. It is noticed that after hard seizures and returning from Emergency these poor children express exponential growth in cognitive development: they begin to use new words, new types of lexical structures, they sing new songs and declare new poems.
It's very strange for me, but I saw this by my own eyes. How it can be?
It is said nowadays that MS might be a neurodegenerative disease but the question is if it so then what are the differences between MS with other neurodegenerative diseases eg, Alzheimers disease or Perkinson disease?
Thanks in advance,..
Can stem cell implants help schizoaffective disorder? If so, what is the closest location to Richmond, Virginia?
I am writing a review article on treatments for cerebral palsy (which I have actually got). I am having great troubles finding clinical trials of controlled studies which have investigated spasticity or other measures of disability in cerebral palsy for many drugs. This hasreally surprised me because I have been prescribed tizanidine in the past and I currently take clonazepam.
There is a lot of research that has investigated the effectiveness of tizanidine, clonazepam, dantrolene and tiagabine on spasticity in people with multiple sclerosis, spinal cord injury and post stroke spasticity, but not CP. This is a bit troubling because cerebral palsy affects a different area of the brain and different neurological/chemical pathways and I am really surprised that other review articles have recommended them but not shown any evidence of their effectiveness in CP (see attached).
Any help would be greatly appreciated.
Most of the papers suggest to use MPTP conc ranging from 40 ug/mL to 200 ug/mL. However, in my case, all the larvae (4 dpf) die after 24 hrs exposed to the MPTP (1 mM), same result goes to the concentration at 30, 40, 50 ug/mL after 24 hrs of exposure. Initially we were thought that our MPTP stock was expired, but we got the same result of the newly purchased MPTP. We prepared the MPTP stock (10 mg/mL) in water and stored the aliquo MPTP in the final concentration of 1 mg/mL at -20. I would be very grateful if anyone could give some advises/suggestions to me on how to treat larvae.
Many thanks in advance
Does anyone have experience with SaeboFlex in neurological hand treatment?
these widenings are causing due to tension and overthinking, Initially it started with tremors, in later stages it giving just pain and swelling in head. Only this information was provided by Doctor.
What are the recent guidelines and advancement in the PD management? Please share your experiences.
Techniques to validate a protocol in home and health care, like image exams with low resources.
My colleague and I discussed about the following three patients with early onset of Parkinson's disease.
Case 1 carries p.A340T & p.N521T of PINK1 gene, both of which variants are not pathogenic according to PDmutDB. Therein, this case does not carry PINK1 gene mutation.
Case 2 carries p.A206T & p.V380L of Parkin gene. p.V380L of Parkin gene is not pathogenic, although function of Parkin p.A206T is unknown. So, case 2 is not a compound heterozygous Parkin mutation carrier.
Case 3 carries p.S167N & p.R366W of Parkin gene. p.S167N of Parkin gene variant is not pathogenic, although p.R366W is pathogenic according to PDmutDB. Therein, case 3 is not a compound heterozygous Parkin mutation carrier.
What would you think? Thanks.
Yue
I have patients with this strange phenomenon who do not have nystagmus or peripheral cerebellar signs.
Can anybody tell me what is usual trend of the EEG segment duration used in feature extraction to process for real-time seizure detection?
Very interestingly, we have come across a high titre of the CMV & HSV in the blood report of a 31 year old legally Blind female, that has been blind for 4 years.
Upon infusing respective antiviral, patient was able to see clearly most of the colors. Has anybody out there studied the Neuro Invasive viral impact on the visual cortex?
I want to compare cytokine levels between a neonatal and adult mouse brain post infection.
Im trying to conduct a neuroprotective assay with SH-SY5Y cells differentiated with RA and TPA to dopaminergic neurons.
There seem to be multiple cell lines capable of similar feats, and some that seem to be used more without differentiation.
Is there any reason to go through the trouble of dual differentiation? or would it be easier and more reliable/reproducible to work with N2A/CATHa/PC12 cell lines, as they seem to be the standard in neuroprotective research.
I understand that SH-SY5Y cells are of human origin, but even still, they dont seem to be heavily used when compared to mouse line.
I see children who have ADHD, LD, or Autism Spectrum disorders, I usually share neurodevelopmental perspectives with parents. An 8 year old male, with early ADHD, now 8, diagnosed 2/15 with aggressive melanotic medulloblastoma, metatstatic drops on the spine. 98% tumor removal by surgery. Any thoughts or research about embryonic factors that may suggest correlation of these two conditions?
I'm trying to load an AM-ester dye in an acute hippocampal brain slice. I am specifically interested in microglia (which are GFP labelled), however, I understand that microglia are particularly difficult to image with these dyes.
We recover for 1 hour in aCSF at room temperature after slicing, then I will incubate with the dye (containing DMSO and diluted in aCSF) at room temperature for 30 min.
Does anyone have tips for getting AM-ester dyes into microglia?
Thanks!
Hello, I'm currently writing a literature based dissertation project about Amyotrophic Lateral Sclerosis and therapeutic drugs required for its treatment. Therefore I was hoping if there would be any clinical trial data information available..? Thanks
Kindly I need a database (raw data or data-set) for Sagittal kinematic data and kinetic data for children with cerebral palsy. and the type of their gaits (crouch gait, jump gait, apparent equinus, true equinus and mild gait).
recurrent episode of left arm weakness, slurred speech positive pronator drift, lasting < I minute. MRI brain normal, EEG mild right hemisphere slow, during the episode.
even though, they discharge him as TIA, not seizure!
Hello, I am interested about some genetic tests. I have 2( female) interesting neuromuscular cases, one with Charcot Marie Tooth and Steinert Miotonia, 38 years old, and other with neuromiotonia, axonal cronic neuropathy and sick sinus syndrome -maybe an interesting association of Chanelopathies, aged 31.
I would like to present this cases but I need collaboration with colleagues specialized in this field!
Sincerely yours,
Adella
i am looking for research materials on the effects of air freshener substances on the brain, i have seen some materials but they are not scientifically backed. i know some of the substances causes toxic encephalopathy, dementia and other neurological diseases but i need their scientific basis
There is always cost to interrupting the normal function of the body. What are the consequences of manipulating the neuro system in delaying dementia?
As part of an ongoing project with ICHOM to develop a global set of outcomes for people with dementia we are interested in hearing about disease specific registries and the outcomes that are used by these projects.
I'm looking for MPNST cell lines that are strictly from sporadic (non NF associated) MPNSTs to compare to NF associated MPNST. I know of STS-26T and HS-Sch-2, but do others exist? There seem to be very few. <br />
A syndrome of keratosis palmo-plantaris congenita, pes planus, onychogryphosis, painless trophic ulcer, clubbing of fingers, periodontosis, arachnodactyly and a peculiar acro-osteolysis has been reported.
Why does Huntington's Disease (HD) affect the brain while Huntington protein (Htt) is expressed in every tissue of the body? Secondly, does the CAG trinucleotide expansion mutation in HD gene (HTT) occurs only in the brain?
After inducing seizures in the two sexes of mice there is a much higher rate in which males have seizures. I cannot figure this out. Please help!
What method of activity monitoring, specifically heart rate intensity and activity duration, have been used to monitor exercise in PD? We are interested in being able to confirm that individuals are exercising at a given percentage of their HR max, and over a specific duration of time...but also want to limit the amount of "interaction" the exerciser needs to have with the monitoring device (number of buttons to push, devices to put on/take off, etc..). We are trying to move towards a more pragmatic method of monitoring - least invasive and least amount of "in-clinic" visits required for downloading of data. We would also like to include as many individuals as possible and therefore are also trying to be conscious of the fact that many folks won't or don't have access to a smart phone, computer, or wireless internet access. We are interested to hear what others have found feasible yet also reliable.
No biological marker has been found in opsoclonus-ataxia syndrome.
It is supposed to be of autoimmune origin, but exact mechanisms remain obscure.
I would like to know more about theories and recent evidence on the topic.
A 19 years old male patient feels muscle function loss on the right side accompanied by parasthesia to the right of the mandibula, which occurs for approximately 20 seconds. It relapses many times a day. In addition there is alveolar bone loss without tooth mobility and bleeding.

Experiments on rats has yielded an optimal dosage to treat induced cerebellar ataxia. But can this dosage be scaled up to humans for this purpose?
Some say it has no effect on non-motor symptoms (NMS); some say it does not always control tremor or bradykinesia very well.
In my (possibly atypical) case it has absolutely no effect on motor symptoms or NMS. But, if I reduce from one 100mg tablet 4 x daily to one tablet 3 x daily, after-3 days I become socially withdrawn. I recover completely within an hour of taking an extra tablet. I have searched the web for information and found… nothing.
To be specific, if a patient has bilateral optic neuritis with positive NMO IgG and asymptomatic spinal cord lesions > 3 segments, is it NMO or NMOSD?
If so, you might be interested in our development of such future devices.
We are a university group and think about starting a company in future. Don´t worry, this is not an advertising or so, I do not want to sell you anything.
We would just like to cordially invite you to take part in a very short poll to get very first impressions of the academics´ and other professionals´ needs.
Please answer six short questions regarding the academic and the pharmaceutical version we have in mind. This takes just five minutes of your time per poll.
For you convenience, you can use the following two survey links:
For the ACADEMIC system (LOW throughput, SEMI-AUTOMATED):
For the PHARMACEUTICAL system (HIGHER throughput, FULLY AUTOMATED):
Let´s shape the future of patch clamp analysis together! You are free to leave your personal data, if you would like to test our prototypes in future (2-3 years)! You can visit our university project site on the following website link:
We have used the model of four soft knots on the sciatic nerve and the model of four soft knots on the saphenous nerve, but were unable to generate the expected hyperalgesia. Animals exhibited no significant changes and sometimes presented hypoesthesia.
Dalakas has given 5 criteria but its not mentioned whether all should be present for diagnosis.
Does neuroinflammation and neurodegeneration induced by continuous infusion (intracerebroventricular) of LPS occur in all CNS neurons or only in specific regions? The literature is rich in research about the hippocampus, but not on other regions. I have special interest in the hypothalamus.
How to carry out In-Vitro evaluation for Alzheimer disease (both cell line and enzyme inhibition assay)?
Diabetic Neuropathy has been on the rise worldwide. Some scientists claim that the copper deficit is also a factor to consider for its etiology.
I’m looking for evidence research and treatment opinions for a rise in sympathetic muscle tone during sleep (4am) and potential with irritated nervous tissue “lose” the adaptive potential that makes sleep “possible”.
I read that the brief repeatable battery of neuropsychological tests, developed by Dr Rao, comes in two different forms. I am particularly interested in the two forms of the SDMT developed for the battery, but can't find them anywhere. Any help?
I would like to know the frequency (percentage) of each location (periventricular, cerebellar, spinal, etc).
We have a clinical problem with a patient with GBS treated promptly with IVIGS. The EMG examination talks about acute motor sensory axonal polineuropathy (AMSAN) with deteriorating clinical course from the first EMG examination. Now the patient is on mechanical ventilation and has no acute infections. At the moment, they have disautonomy and tetraparesia. 21 days ago they received 2 gr/kg in five days of IVIGS. What would you do now?
Nothing,
A second course of IVIGS,
Plasmapheresis?